Lista de obras -

A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.

artículo científico publicado en 2018

A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies

artículo científico publicado en 2012

Activation and lysis of human CD4 cells latently infected with HIV-1

artículo científico publicado en 2015

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report

artículo científico publicado en 2020

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

artículo científico publicado en 2011

Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline

artículo científico publicado en 2014

Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization

artículo científico publicado en 2019

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

scholarly article by Nicole Doria-Rose published in 2021

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

artículo científico publicado en 2009

Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting

article

Correction for Acharya et al., Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites

article

Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

artículo científico publicado en 2016

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

artículo científico publicado en 2011

Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

artículo científico publicado en 2015

Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.

artículo científico publicado en 2017

De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts

artículo científico publicado en 2013

Defining the risk of SARS-CoV-2 variants on immune protection

artículo científico publicado en 2022

Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization

artículo científico publicado en 2013

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

artículo científico publicado en 2014

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

artículo científico publicado en 2020

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

artículo científico publicado en 2021

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

artículo científico publicado en 2021

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

artículo científico publicado en 2016

Eliminating antibody polyreactivity through addition of N-linked glycosylation

artículo científico publicado en 2015

Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain

scientific article published on 04 March 2009

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

artículo científico publicado en 2014

Enhancing the Solubility of HIV-1-neutralizing Antibody 10E8.

artículo científico publicado en 2014

Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1

artículo científico publicado en 2018

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

artículo científico publicado en 2020

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

artículo científico publicado en 2011

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

artículo científico publicado en 2008

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

artículo científico publicado en 2016

HIV-1 Cross-reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Non-human Primate

artículo científico publicado en 2017

HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins ⬇️

artículo científico publicado el 8 de agosto de 2012

HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies

artículo científico publicado en 2015

HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice

scientific article published on 17 February 2020

HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes

artículo científico publicado en 2012

Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites

artículo científico publicado en 2013

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

artículo científico publicado en 2008

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

artículo científico publicado en 2016

Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature

artículo científico publicado en 2020

Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies

artículo científico publicado en 2011

Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry

artículo científico publicado en 2019

Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting

artículo científico publicado en 2017

Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection

artículo científico publicado en 2015

Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 ⬇️

artículo científico publicado el 29 de junio de 2011

Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment

artículo científico publicado en 2009

Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding

artículo científico publicado en 2016

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

artículo científico publicado en 2015

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

artículo científico publicado en 2016

Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen

artículo científico publicado en 2020

Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation

artículo científico publicado en 2017

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity

artículo científico publicado en 2018

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

artículo científico publicado en 2010

Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

artículo científico publicado en 2020

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

artículo científico publicado en 2020

Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site ⬇️

artículo científico publicado el 14 de marzo de 2012

Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics

artículo científico publicado en 2012

Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6

artículo científico publicado en 2014

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

artículo científico publicado en 2009

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

artículo científico publicado en 2015

Structure of BMS-806, a Small-molecule HIV-1 Entry Inhibitor, Bound to BG505 SOSIP.664 HIV-1 Env Trimer.

artículo científico publicado en 2014

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

artículo científico publicado en 2011

Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity

artículo científico publicado en 2017

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

artículo científico publicado en 2018

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

artículo científico publicado en 2016

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

artículo científico publicado en 2017

VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage

artículo científico publicado en 2020

Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability

scientific article published on 12 November 2019

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

artículo científico publicado en 2015

Variable Dependence on Glycan Recognition within a Lineage of V1V2-directed HIV Neutralizing Antibodies

artículo científico publicado en 2014

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

artículo científico publicado en 2015

Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop

artículo científico publicado en 2017

Lista de obras de

A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.

A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies

Activation and lysis of human CD4 cells latently infected with HIV-1

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline

Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting

Correction for Acharya et al., Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites

Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.

De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts

Defining the risk of SARS-CoV-2 variants on immune protection

Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

Eliminating antibody polyreactivity through addition of N-linked glycosylation

Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

Enhancing the Solubility of HIV-1-neutralizing Antibody 10E8.

Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

HIV-1 Cross-reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Non-human Primate

HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins ⬇️

HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies

HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice

HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes

Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature

Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies

Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry

Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting

Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection

Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 ⬇️

Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment

Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen

Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site ⬇️

Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics

Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6

Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

Structure of BMS-806, a Small-molecule HIV-1 Entry Inhibitor, Bound to BG505 SOSIP.664 HIV-1 Env Trimer.

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage

Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

Variable Dependence on Glycan Recognition within a Lineage of V1V2-directed HIV Neutralizing Antibodies

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop